A previous study reported that EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in LUAD, and the MEK inhibitor U0126 significantly reversed the promoting effect of EphA10 overexpression on LUAD cells [37]. The gene discussed is EPHA10; the disease is neoplasm.